Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319139 | 0.83 | GAA (0.41) | GAANOS3NOS2CHRM1THRB | |
| SCHEMBL28423485 | 0.81 | GAA (0.43) | GAANOS3NOS2CHRM1THRB | |
| SCHEMBL28429967 | 0.81 | GAA (0.43) | GAANOS3NOS2CHRM1THRB | |
| SCHEMBL28423487 | 0.81 | GAA (0.43) | GAANOS3NOS2CHRM1THRB | |
| SCHEMBL8790971 | 0.80 | GAA (0.40) | GAANOS3NOS2MAPTKDM4E | |
| SCHEMBL18979956 | 0.80 | GAA (0.37) | GAACHRM1THRBATML3MBTL1 | |
| SCHEMBL19995830 | 0.79 | HPGD (0.48) | GAATHRBATML3MBTL1PKM | |
| SCHEMBL25553449 | 0.78 | SMN1; SMN2 (0.43) | GAAPKMMAPTKDM4EALDH1A1 | |
| SCHEMBL22680079 | 0.77 | GAA (0.43) | GAANOS3NOS2MAPTALDH1A1 | |
| SCHEMBL22680078 | 0.77 | GAA (0.43) | GAANOS3NOS2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803801-B2 | Aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO, INC. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7803801-B2 | Aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO, INC. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7803801-B2 | Aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO, INC. (JP) | 2010-09-28 | — | — | US | disclosed |
| EP-1854793-A1 | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY | Japan Tobacco, Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | SYK, BTK, ZAP70 | GAA 3662/4885NOS3 91/4885NOS2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.